Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$90.20−1.24 (-1.36%)
Close on Nov 12, 2026Market cap $7.08BP/E –Yield –
Abivax EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -4.83 EUR. The highest annual figure on record is -2.75 EUR in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4.83 EUR | – |
| FY2024 | Dec 31, 2024 | -2.80 EUR | – |
| FY2023 | Dec 31, 2023 | -3.43 EUR | – |
| FY2022 | Dec 31, 2022 | -3.18 EUR | – |
| FY2021 | Dec 31, 2021 | -2.75 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1.47 EUR | – |
| Q1 FY2026 | Mar 31, 2026 | -0.61 EUR | – |
| Q3 FY2025 | Sep 30, 2025 | -2.10 EUR | – |
| Q2 FY2025 | Jun 30, 2025 | -0.76 EUR | – |
| Q1 FY2025 | Mar 31, 2025 | -0.83 EUR | – |
| Q3 FY2024 | Sep 30, 2024 | -0.87 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -0.62 EUR | – |
| Q1 FY2024 | Mar 31, 2024 | -0.68 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?